Applicability of theREDUCE-ITtrial to theFAST-MIregistry. Are the results of randomized trials relevant in routine clinical practice?
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Applicability of theREDUCE-ITtrial to theFAST-MIregistry. Are the results of randomized trials relevant in routine clinical practice? |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Ferrieres J, Bataille V, Puymirat E, Schiele F, Simon T, Danchin N, Investigators FAST-MI |
Journal | CLINICAL CARDIOLOGY |
Volume | 43 |
Pagination | 1260-1265 |
Date Published | NOV |
Type of Article | Article |
ISSN | 0160-9289 |
Mots-clés | eicosapentaenoic acid, omega-3 icosapent ethyl, Randomized trial, Registry, Statins |
Résumé | Background The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosapent ethyl vs placebo in statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol (LDL-C). Hypothesis Are the results of the REDUCE-IT trial applicable to the French registry on acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) population? Methods Data were extracted from the FAST-MI 2010 and 2015 registries. We applied the REDUCE-IT enrolment criteria (triglycerides 150-500 mg/dL and LDL-C 40-100 mg/dL on statins) to the FAST-MI population in patients aged >= 45 years who had detailed lipid values postacute hospitalization, focusing on their clinical profile and cardiovascular prognosis. Results Of the 3789 FAST-MI patients with a full lipid profile (median 11.1 [IQR 7.6-17.4] months after hospitalization for myocardial infarction), 472 (12.5%; 95% CI 11.4-13.5) met the eligibility criteria for REDUCE-IT (REDUCE-IT-like group). The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial. The residual cardiovascular risk related to elevated triglycerides in the REDUCE-IT-like group was similar to the risk in the REDUCE-IT trial. Conclusions If the results of REDUCE-IT are applied to patients hospitalized for a myocardial infarction in France, 12.5% of these patients could benefit from a strategy of high-dose omega-3 icosapent ethyl on top of contemporary therapy including statins to improve their clinical outcomes. |
DOI | 10.1002/clc.23437 |